Balanza Núria, Erice Clara, Ngai Michelle, McDonald Chloe R, Weckman Andrea M, Wright Julie, Richard-Greenblatt Melissa, Varo Rosauro, López-Varela Elisa, Sitoe Antonio, Vitorino Pio, Bramugy Justina, Lanaspa Miguel, Acácio Sozinho, Madrid Lola, Baro Bàrbara, Kain Kevin C, Bassat Quique
ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain.
Sandra-Rotman Centre for Global Health, Toronto General Research Institute, University Health Network-Toronto General Hospital, Toronto, Ontario, Canada.
PLOS Glob Public Health. 2023 Feb 23;3(2):e0001553. doi: 10.1371/journal.pgph.0001553. eCollection 2023.
Pneumonia is a leading cause of child mortality. However, currently we lack simple, objective, and accurate risk-stratification tools for pediatric pneumonia. Here we test the hypothesis that measuring biomarkers of immune and endothelial activation in children with pneumonia may facilitate the identification of those at risk of death. We recruited children <10 years old fulfilling WHO criteria for pneumonia and admitted to the Manhiça District Hospital (Mozambique) from 2010 to 2014. We measured plasma levels of IL-6, IL-8, Angpt-2, sTREM-1, sFlt-1, sTNFR1, PCT, and CRP at admission, and assessed their prognostic accuracy for in-hospital, 28-day, and 90-day mortality. Healthy community controls, within same age strata and location, were also assessed. All biomarkers were significantly elevated in 472 pneumonia cases versus 80 controls (p<0.001). IL-8, sFlt-1, and sTREM-1 were associated with in-hospital mortality (p<0.001) and showed the best discrimination with AUROCs of 0.877 (95% CI: 0.782 to 0.972), 0.832 (95% CI: 0.729 to 0.935) and 0.822 (95% CI: 0.735 to 0.908), respectively. Their performance was superior to CRP, PCT, oxygen saturation, and clinical severity scores. IL-8, sFlt-1, and sTREM-1 remained good predictors of 28-day and 90-day mortality. These findings suggest that measuring IL-8, sFlt-1, or sTREM-1 at hospital presentation can guide risk-stratification of children with pneumonia, which could enable prioritized care to improve survival and resource allocation.
肺炎是儿童死亡的主要原因。然而,目前我们缺乏用于小儿肺炎的简单、客观且准确的风险分层工具。在此,我们检验这样一个假设:检测肺炎患儿免疫和内皮激活的生物标志物可能有助于识别有死亡风险的患儿。我们招募了2010年至2014年期间符合世界卫生组织肺炎标准且入住曼希卡区医院(莫桑比克)的10岁以下儿童。我们在入院时测量了血浆中白细胞介素-6(IL-6)、白细胞介素-8(IL-8)、血管生成素-2(Angpt-2)、可溶性髓系细胞触发受体-1(sTREM-1)、可溶性血管内皮生长因子受体-1(sFlt-1)、可溶性肿瘤坏死因子受体-1(sTNFR1)、降钙素原(PCT)和C反应蛋白(CRP)的水平,并评估它们对住院、28天和90天死亡率的预测准确性。还评估了同一年龄层和同一地点的健康社区对照。与80名对照相比,472例肺炎病例中所有生物标志物均显著升高(p<0.001)。IL-8、sFlt-1和sTREM-1与住院死亡率相关(p<0.001),并且显示出最佳的区分能力,曲线下面积(AUROC)分别为0.877(95%置信区间:0.782至0.972)、0.832(95%置信区间:0.729至0.935)和0.822(95%置信区间:0.735至0.908)。它们的表现优于CRP、PCT、血氧饱和度和临床严重程度评分。IL-8 sFlt-1和sTREM-1仍然是28天和90天死亡率的良好预测指标。这些发现表明,在患儿入院时检测IL-8、sFlt-1或sTREM-1可以指导肺炎患儿的风险分层,这能够实现优先护理以提高生存率和资源分配。